Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

NCT06527690 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT06527690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06527690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2025
Completion date
February 28, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, homologous recombination deficiency, prostate cancer